Tuesday, July 08, 2014 10:18:03 AM
$OXGN DD post. Their key catalyst is that they present the full data NCI/GOG data in the September. News is expected at ESMO 2014 Congress Sep 26 - 30 2014. $OXGN is also listed on the ETA (European Thyroid Association) 2014 meeting in early September. http://t.co/cLLQ6RamWu . ESMO 2014 will follow that conference is the key GOG full data release.
The company has a market cap of only 39m. It has an O/S of 15.3m and a float of 13.4m. Company just did a recent financing at $2.96/share. OXGN has a 52wk low of $1.96 & a 52wk high of $5.40.
Oxigene Corporate Presentation May 2014..$OXGN http://bit.ly/1jfm32B
OXGN..Wainright assumes a buy on 6/26/14. http://www.smarteranalyst.com/2014/06/26/h-c-wainright-assumes-buy-as-oxigene-displays-tremendous-potential-upside/
OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering. This offering was done at $2.96/share.
http://finance.yahoo.com/news/oxigene-inc-announces-16-million-130000685.html
@adamfeuerstein: $OXGN Surprises With Positive Ovarian Cancer Study Success —> http://t.co/67O3wta2B4
@FierceBiotech: Oxigene roars back to life on positive ovarian cancer study. http://t.co/fI9oX3ItGX
OXiGENE, Inc. Discusses Q4 2013 Results (Webcast) http://t.co/JtSc00IswU $OXGN Listen to the 4 minute mark on the details of the results. The 6:45 mark discusses full data presentation soon in H2 2014.
Oxigene Discusses Q1 2014 results:
http://seekingalpha.com/article/2196453-oxigenes-oxgn-ceo-peter-langecker-on-q1-2014-results-earnings-call-transcript
“I’d also like to mention that given the positive developments in the first quarter, we are increasingly excited about our future prospects at OXiGENE. Our cash position is stronger, and we have significant new Phase II data that opens up opportunities for future clinical development and exploring potential partnerships.”
OXGN-Zybrestat
http://www.oxigene.com/product-development/zybrestat
$OXGN..12.43 % of float is sold short
The company has a market cap of only 39m. It has an O/S of 15.3m and a float of 13.4m. Company just did a recent financing at $2.96/share. OXGN has a 52wk low of $1.96 & a 52wk high of $5.40.
Oxigene Corporate Presentation May 2014..$OXGN http://bit.ly/1jfm32B
OXGN..Wainright assumes a buy on 6/26/14. http://www.smarteranalyst.com/2014/06/26/h-c-wainright-assumes-buy-as-oxigene-displays-tremendous-potential-upside/
OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering. This offering was done at $2.96/share.
http://finance.yahoo.com/news/oxigene-inc-announces-16-million-130000685.html
@adamfeuerstein: $OXGN Surprises With Positive Ovarian Cancer Study Success —> http://t.co/67O3wta2B4
@FierceBiotech: Oxigene roars back to life on positive ovarian cancer study. http://t.co/fI9oX3ItGX
OXiGENE, Inc. Discusses Q4 2013 Results (Webcast) http://t.co/JtSc00IswU $OXGN Listen to the 4 minute mark on the details of the results. The 6:45 mark discusses full data presentation soon in H2 2014.
Oxigene Discusses Q1 2014 results:
http://seekingalpha.com/article/2196453-oxigenes-oxgn-ceo-peter-langecker-on-q1-2014-results-earnings-call-transcript
“I’d also like to mention that given the positive developments in the first quarter, we are increasingly excited about our future prospects at OXiGENE. Our cash position is stronger, and we have significant new Phase II data that opens up opportunities for future clinical development and exploring potential partnerships.”
OXGN-Zybrestat
http://www.oxigene.com/product-development/zybrestat
$OXGN..12.43 % of float is sold short
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
